Editas Medicine, Inc. (EDIT) News
Filter EDIT News Items
EDIT News Results
|Loading, please wait...|
EDIT News Highlights
- EDIT's 30 day story count now stands at 8.
- Over the past 22 days, the trend for EDIT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about EDIT are GENE, AMD and CRSP.
Latest EDIT News From Around the Web
Below are the latest news stories about EDITAS MEDICINE INC that investors may wish to consider to help them evaluate EDIT as an investment opportunity.
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks.
Key Insights Institutions' substantial holdings in Editas Medicine implies that they have significant influence over...
Investors may want to strongly consider this new list of stocks to buy that could double in 2024.
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?
Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two.
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.
The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed. But even before then, the roadmap gave researchers the opportunity to develop gene therapies to correct genetic abnormalities. Gene editing, which seeks to directly alter a patient’s genome itself, is the next stage. If successful, it may provide a viable treatment for many previously untreatable genetic disorders. That is why
Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.
Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript November 3, 2023 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.00055, expectations were $-0.64. Operator: Good morning, and welcome to Editas Medicine’s Third Quarter Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this […]